Epidemiology and costs of diabetes mellitus in Switzerland: an analysis of health care claims data, 2006 and 2011

BMC Endocrine Disorders

Oliver Reich¹  Roland Rapold¹  Matthias Schwenkglenks²  Carola A Huber¹ 

[1] Department of Health Sciences, Helsana Insurance Group, P.O. Box, Zürich, Switzerland;Institute of Social and Preventive Medicine, University of Zürich, 8001 Zürich, Switzerland

关键词: Costs;    Mortality;    Incidence;    Prevalence;    Diabetes;   

Others  :  864920
DOI  :  10.1186/1472-6823-14-44

 received in 2013-11-13, accepted in 2014-05-28,  发布年份 2014

【 摘 要 】

Background

Quantifying the burden of diabetes mellitus is fundamental for managing patients in health service delivery systems and improves the understanding of the importance of prevention and early intervention of diabetes. In Switzerland, epidemiological data on diabetes are very scarce. In this study we provide a first national overview of the current situation of diabetes mellitus in Switzerland as well as the development of the prevalence, incidence, mortality and costs between 2006 and 2011.

Methods

Using health care claims data of a large health insurance group, current epidemiology and costs were determined from a sample of adult enrollees in 2011. The identification of patients with diabetes was based on prescription data of diabetes related drugs using the Anatomical Therapeutic Chemical Classification as proxy for clinical diagnosis. We further evaluated changes in epidemiology and costs between 2006 and 2011. All results were weighted with census data to achieve an extrapolation to the Swiss general population level.

Results

A total of 920’402 patients were enrolled in 2011 and 49’757 (5.4%) were identified as diabetes cases. The extrapolated overall prevalence of diabetes in Switzerland was 4.9% (2006, 3.9%). The incidence was 0.58% in 2011 (2007, 0.63%). The extrapolated mortality rate was 2.6% with no significant change over time. Annual diabetes costs to the mandatory health insurance increased from EUR 5,036 per patient in 2006 to EUR 5’331 per patient in 2011.

Conclusions

This study shows a high medical and economic burden of diabetes. The prevalence and costs of diabetes in Switzerland increased substantially over time. Findings stress the need for public health strategies to manage patients with chronic conditions and optimize resource allocation in health service delivery systems.

【 授权许可】

   
2014 Huber et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Whiting DR, Guariguata L, Weil C, Shaw J: IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94:311-321.
• [2]Struijs JN, Baan CA, Schellevis FG, Westert GP, van den Bos GA: Comorbidity in patients with diabetes mellitus: impact on medical health care utilization. BMC Health Serv Res 2006, 6:84. BioMed Central Full Text
• [3]Mo F, Pogany LM, Li FC, Morrison H: Prevalence of diabetes and cardiovascular comorbidity in the Canadian Community Health Survey 2002–2003. Scientific World Journal 2006, 6:96-105.
• [4]Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, Connolly V, King H: The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005, 28:2130-2135.
• [5]Lipscombe LL, Hux JE: Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995–2005: a population-based study. Lancet 2007, 369:750-756.
• [6]Köster I, Huppertz E, Hauner H, Schubert I: Direct costs of diabetes mellitus in Germany - CoDiM 2000–2007. Exp Clin Endocrinol Diabetes 2011, 119:377-385.
• [7]Jönsson B, CODE-2 Advisory Board: Revealing the cost of Type II diabetes in Europe. Diabetologia 2002, 45:S5-S12.
• [8]American Diabetes Association: Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008, 31:596-615.
• [9]Kaiser A, Vollenweider P, Waeber G, Marques-Vidal P: Prevalence, awareness and treatment of type 2 diabetes mellitus in Switzerland: the CoLaus study. Diabet Med 2012, 29:190-197.
• [10]Bopp M, Zellweger U, Faeh D: Routine data sources challenge international diabetes Federation extrapolations of national diabetes prevalence in Switzerland. Diabetes Care 2011, 34:2387-2389.
• [11]Rizza A, Kaplan V, Senn O, Rosemann T, Bhend H, Tandjung R, FIRE study group: Age- and gender-related prevalence of multimorbidity in primary care: the swiss fire project. BMC Fam Pract 2012, 13:113. BioMed Central Full Text
• [12]Schmitt-Koopmann I, Schwenkglenks M, Spinas GA, Szucs TD: Direct medical costs of type 2 diabetes and its complications in Switzerland. Eur J Public Health 2004, 14:3-9.
• [13]Weber C, Schneider B, Lodwig V, Holm MV, Neeser K: Cost impact of blood glucose self-monitoring on complications of type 2 diabetes: a Swiss perspective (ROSSO study No.11). Swiss Med Wkly 2007, 137:545-550.
• [14]O‘Shea M, Teeling M, Bennett K: The prevalence and ingredient cost of chronic comorbidity in the Irish elderly population with medication treated type 2 diabetes: a retrospective cross-sectional study using a national pharmacy claims database. BMC Health Serv Res 2013, 13:23. BioMed Central Full Text
• [15]WHO Collaborating Centre for Drug Statistics Methodology: Guidelines for ATC classification and DDD assignment 2011. Oslo: WHO; 2010.
• [16]Lamers LM, van Vliet RC: The Pharmacy-based Cost Group model: validating and adjusting the classification of medications for chronic conditions to the Dutch situation. Health Policy 2004, 68:113-121.
• [17]Tu K, Manuel D, Lam K, Kavanagh D, Mitiku TF, Guo H: Diabetics can be identified in an electronic medical record using laboratory tests and prescriptions. J Clin Epidemiol 2011, 64:431-435.
• [18]Common Institution of Health Insurance Law 2012 Gemeinsame Einrichtung Krankenversicherungsgesetz, KVG; [http://www.kvg.org/de/risikoausgleich-_content---1--1047.html webcite]
• [19]Swiss Federal Office of Statistic. [http://www.bfs.admin.ch/bfs/portal/de/index/themen/01/02/blank/key/alter/gesamt.html webcite]
• [20]Wilke T, Ahrendt P, Schwartz D, Linder R, Ahrens S, Verheyen F: Incidence and prevalence of type 2 diabetes mellitus in Germany: an analysis based on 5.43 million patients. Dtsch Med Wochenschr 2013, 138:69-75.
• [21]Tabaei BP, Chamany S, Driver CR, Kerker B, Silver L: Incidence of self-reported diabetes in New York City, 2002, 2004, and 2008. Prev Chronic Dis 2012, 9:E114.
• [22]Monesi L, Baviera M, Marzona I, Avanzini F, Monesi G, Nobili A, Tettamanti M, Cortesi L, Riva E, Fortino I, Bortolotti A, Fontana G, Merlino L, Roncaglioni MC: Prevalence, incidence and mortality of diagnosed diabetes: evidence from an Italian population-based study. Diabet Med 2012, 29:385-392.
• [23]Marques-Vidal P, Bovet P, Paccaud F, Chiolero A: Changes of overweight and obesity in the adult Swiss population according to educational level, from 1992 to 2007. BMC Public Health 2010, 10:87. BioMed Central Full Text
• [24]Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Li H, Jiang Y, An Y, Shuai Y, Zhang B, Zhang J, Thompson TJ, Gerzoff RB, Roglic G, Hu Y, Bennett PH: The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008, 371:1783-1789.
• [25]Gregg EW, Gu Q, Cheng YJ, Narayan KM, Cowie CC: Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med 2007, 147:149-155.
• [26]Preis SR, Hwang SJ, Coady S, Pencina MJ, D‘Agostino RB Sr, Savage PJ, Levy D, Fox CS: Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009, 119:1728-1735.
• [27]Dall TM, Zhang Y, Chen YJ, Quick WW, Yang WG, Fogli J: The economic burden of diabetes. Health Aff (Millwood) 2010, 29:297-303.
• [28]Kanavos P, van den Aardweg S, Schurer W: Diabetes expenditures, burden of disease and management in 5 EU countries. LSE Health, London School of Economics; [http://www2.lse.ac.uk/LSEHealthAndSocialCare/research/LSEHealth/MTRG/LSEDiabetesReport26Jan2012.pdf webcite]
• [29]Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, Nichols G: Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87:293-301.
• [30]Leon DA: Trends in European life expectancy: a salutary view. Int J Epidemiol 2011, 40:271-277.
• [31]Coleman K, Austin BT, Brach C, Wagner EH: Evidence on the Chronic Care Model in the new millennium. Health Aff (Millwood) 2009, 28:75-85.
• [32]Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, Hämäläinen H, Härkönen P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J, Finnish Diabetes Prevention Study Group: Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006, 368:1673-1679.